What are the causes of low Parathyroid Hormone (PTH) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Low PTH levels should be managed by adjusting dialysate calcium concentration to stimulate PTH production and prevent adynamic bone disease, with a target intact PTH level of at least 100 pg/mL (11.0 pmol/L) 1. When managing low PTH levels, it is essential to consider the underlying cause and the patient's overall clinical context. In patients with chronic kidney disease, low PTH levels can be associated with adynamic bone disease, which can be stimulated by reducing the dialysate calcium concentration to 1.5 to 2.0 mEq/L 1. This approach can help increase bone turnover and prevent low-turnover bone disease. However, it is crucial to monitor PTH levels closely to avoid overstimulation and the development of high-turnover bone disease.

Key considerations in managing low PTH levels include:

  • Adjusting dialysate calcium concentration to stimulate PTH production 1
  • Monitoring intact PTH levels to avoid overstimulation and high-turnover bone disease 1
  • Maintaining a target intact PTH level of at least 100 pg/mL (11.0 pmol/L) 1
  • Being aware of the potential risks and benefits of different dialysate calcium concentrations, including the risk of cardiac arrhythmias with lower calcium dialysates 1

By taking a thoughtful and individualized approach to managing low PTH levels, clinicians can help prevent complications and improve patient outcomes. Regular monitoring of serum calcium, phosphorus, and magnesium levels is also essential to ensure that the patient's mineral metabolism is well-controlled 1.

From the Research

Definition and Characteristics of Low PTH

  • Low PTH, also known as hypoparathyroidism, is characterized by hypocalcemia, hyperphosphatemia, and low or inappropriately normal levels of parathyroid hormone (PTH) 2.
  • PTH is a key calcium regulating hormone essential for calcium homeostasis, vitamin D-dependant calcium absorption, renal calcium reabsorption, and renal phosphate clearance 2.

Causes of Low PTH

  • The most common cause of hypoparathyroidism is iatrogenic in the setting of anterior neck surgery 2, 3.
  • Other causes include autoimmune diseases, genetic abnormalities, destruction or infiltrative disorders of the parathyroids, hypomagnesemia, and hypermagnesemia 2.

Symptoms and Diagnosis of Low PTH

  • Symptoms of hypocalcemia include neuromuscular irritability, perioral numbness, paresthesias, tingling, seizures, and bronchospasm 2, 3.
  • Diagnosis is made through a comprehensive history, physical examination, and relevant biochemical investigation 2.

Treatment of Low PTH

  • Treatment of symptomatic or profound asymptomatic hypocalcemia involves rapid intravenous administration of calcium and oral supplementation of vitamin D metabolites 2.
  • Oral calcium and vitamin D analogs are critical in the treatment of hypocalcemia, and thiazide diuretics can enhance renal calcium reabsorption and increase serum calcium 2.
  • PTH replacement therapy has emerged as a new treatment option, which can improve serum calcium and lower serum phosphate levels, as well as reduce the doses of calcium and calcitriol supplementation required 3, 4, 5.
  • Recombinant human PTH(1-84) has been approved in the United States and Europe for the management of hypoparathyroidism, but its effect on long-term complications is still being evaluated 3, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Hypoparathyroidism.

Best practice & research. Clinical endocrinology & metabolism, 2012

Research

Hypoparathyroidism.

Nature reviews. Disease primers, 2017

Research

PTH(1-84) replacement therapy for the treatment of hypoparathyroidism.

Expert review of endocrinology & metabolism, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.